Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited has announced the cessation of 30,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for its stakeholders, reflecting the challenges in meeting certain operational conditions.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company specializes in regenerative medicine, aiming to address significant unmet medical needs across various therapeutic areas.
YTD Price Performance: -31.82%
Average Trading Volume: 417,938
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.26B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.